Experimental clotting factor could stop Life-Threatening bleeding in ICU patients
NCT ID NCT06118372
Summary
This early-stage study is testing the safety of a lab-made clotting factor (recombinant von Willebrand Factor) in adults on ECMO life support who have severe, hard-to-control bleeding. The treatment aims to help the blood clot properly and reduce dangerous bleeding. Researchers will give the treatment once to 12 patients and closely monitor for side effects and how the body processes it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLEEDING DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UVA Hospital
RECRUITINGCharlottesville, Virginia, 22903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.